Oxaliplatin: The first DACH platinum in clinical practice;Oxaliplatine: Le premier DACH platine en clinique

Bulletin du Cancer

Volumn 84, Issue 6, 1997, Pages 665-673

  Soulié, Patrick ^a,c   Raymond, Eric ^a   Brienza, Silvano ^b   Cvitkovic, Esteban ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b Debiopharm   (France)

^c CENTRE RENÉ HUGUENIN   (France)

Author keywords

DACH platinums; Oxaliplatin

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOPLATIN; CISPLATIN; FLUOROURACIL; FOLINIC ACID; NAVELBINE; OXALIPLATIN; PLATINUM DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ESOPHAGUS CANCER; GLIOMA; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLIC ACID; HUMANS; MALE; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES; SURVIVAL ANALYSIS;

EID: 0030802911     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J. Natl Cancer Inst 1995 ; 87 : 573-80.
2. Burchenal JH, Kalaher K, Dew K, et al. Rationale For the development of platinum analogs. Cancer Treat Rep 1979 ; 63 : 1493-8.
3. Christian MC. The current status of new platinum analogs. Semin Oncol 1992 ; 19 : 720-33.
4. Burchenal JH, Lokys L, Turkevich J, et al. 1,2-diaminocyclohexane platinum derivatives of potential clinical value. Recent Results Cancer Res 1980 ; 74 : 146-55.
5. Schilder RJ, LaCreta FP, Perez RP, et al. Phase I and pharmacokinetics study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Ses 1994 ; 54 : 709-17.
6. Tashiro R, Kawada Y, Sakuri Y, et al. Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane) platinum (II) : new experimental data. Biomed Pharmacother 1989 ; 43 : 251.
7. Mathé G, Kidani Y, Sekiguchi M, et al. Oxalato-platinum or I-OHP, a third generation platinum complex : an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 1989 ; 43 : 237-50.
8. Boudny V, Vrana O, Gaucheron F, et al. Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum (II) complexes. Nucleic Acids Res 1992 ; 20(2) : 267-72.
9. Inagaki K, Kidani Y. Differences in binding of (1,2-cyclohexane) platinum (II) isomers with d(GpG). Inorg Chem 1986 ; 25 : 1-3.
10. Kidani Y. Oxaliplatin. Drugs Future 1989 ; 14 (6) : 529-32.
11. Kohn KW. Molecular mechanisms of cross-linking by alkylating agents and platinum complexes. In : Sartorelli AC, Lazo JS, Bertino JR, eds. Molecular actions and targets for cancer chemotherapeutic agents. New York: Academic Press, 1981.
12. Micetich KC, Barnes D, Erickson LC. A comparative study of the cytotaxicity and DNA-damaging effects of cis-(diammino) (1,1-cyclobutanedicarboxylaton)-platinum (II) and cis-diamminedichloroplatinum (II) on L1210 cells. Cancer Res 1985 ; 45 : 4043-7.
13. Jennerwein MM, Eastman A, Khokhar A. Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexane platinum (II) complexes. Chem Biol Interactions 1989 ; 70 : 39-49.
14. Mathé G, Chenu E, Bourut C, et al. Experimental study of three platinum complexes : CDDP, CBDCA and I-OHP on L1210 leukemia. Alternate or simultaneous association of two platinum complexes. Proc Am Assoc Cancer Res 1989 ; 30 : 471.
15. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Research 1993 ; 53 : 5970-6.
16. Raymond E, Goldwasser F, Djelloul, et al. A rationale for oxaliplatin-based combinations in colon cancer. Proc NCI-EORTC 1996 ; abst. 126.
17. Myers TG, Paull KD, Fojo AT, et al. Multivariate analysis of high-flux screening data using the DISCOVER computer program package : integrated analysis of activity patterns and molecular structure features of platinum complexes. Proc Am Assoc Cancer Res 1994 ; 35 : 371.
18. Alvarez M, Ortuzar W, Rixe O, et al. Cross resistance patterns of cell lines selected with platinum suggest differences in the activities and mechanisms of resistance of platinum analogues. Proc Am Assoc Cancer Res 1994 ; 35 : 439.
19. Ortuzar W, Paull K, Rixe O, et al. Comparison of the activity of cisplatin (CP) and oxaliplatin (OXALI) alone or in combination in parental and drug resistant sublines. Proc Am Assoc Cancer Res 1994 ; 35 : 332.
20. Lokiec F. Pharmacocinétique clinique de l'oxaliplatine. La Lettre du Cancérologue 1996 ; V (suppl.) 4 : 15-7.
21. Gamelin E, Allain P, Delva R, et al. Study of long term cumulative pharmacokinetic characteristics of oxaliplatin with inductively coupled plasma mass spectrometry. An open monocentric study of 17 patients. Proc Am Soc Oncol 1996 ; 15 : 471.
22. Massari C, Brienza S, Rotarski M. Oxaliplatin, Transplatin®: comparative pharmacokinetics in normal and impaired renal Function patients. Proc Am Assoc Cancer Res 1994 ; 35 : 242.
23. Gamelin E, Allain P, Maillart P, et al. Long-term pharmacokinetic behavior of platinum after cisplatin administration. Cancer Chemother Pharmacol 1995 ; 37 : 97-102.
24. Extra JM, Espie M, Calvo F, et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemoter Pharmacol 1990 ; 25 : 299-303.
25. Caussanel JP, Lévi F, Brienza S, et al. Phase I trial of 5-day continous venous infusion of oxaliplatin at circadian rhythm modulated rate compared with constant rate. J Natl Cancer Inst 1990 ; 82 : 1046-50.
26. Brienza S, Vignoud J, Itzhaki M. Oxaliplatin (L-OHP): global safety in 682 patients. Proc Am Soc Clin Oncol 1995 ; 14 : 209.
27. Brienza S, Fandi A, Hugret F, et al. Neurotoxicity (NTX) of long term oxaliplatin (L-OHP). Proc Am Assoc Cancer Res 1993 ; 34 : 406.
28. Llory JF, Soulie P, Cvitkovic E, et al. Feasibility of high-dose platinum delivery with combined carboplatin and oxaliplatin. J Natl Cancer Inst 1994 ; 86 : 1098-9.
29. Garrino C, Cvitkovic E, Soulie P, et al. Preliminary report on the tolerance of transplatin (L-OHP) cisplatin association alone (Bi) or in combination with ifosfamide and epirubicin (Bic) in platinum (Pt) pretreated patients. Proc Am Soc Oncol 1994 ; 13 : 143.
30. Soulie P, Llory JF, Fereres M, et al. Preliminary results of an active oxaliplatin (L-OHP)-CDDP association based salvage program in pretreated germ cell tumors (GCT). Proc Am Soc Oncol 1994 ; 13 : 250.
31. Misset JL, Kidani Y, Gastiaburu J, et al. Oxalatoplatinum (I-OHP) : experimental and clinical studies. In : Howell SB, ed. Platinum and other metal coordination compounds in cancer chemotherapy. New York: Plenum Press, 1991 ; 369-75.
32. Lévi F, Perpoint B, Garufi C, et al. Oxaliplatin activity against metastatic colorectal cancer : a phase II study of 5-day continous venous infusion at circadian-rhythm modulated rate. Eur J Cancer 1993 ; 29A : 1284-93.
33. Machover D, Diaz-Rubio E, De Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Annals of Oncol 1996 ; 7 : 95-8.
34. Lévi F, Machover D, Marty M, et al. Oxaliplatin (L-OHP): summary of results in advanced colorectal cancer (ACC). Eur J Cancer 1995 ; 31A (suppl. 5) : 738.
35. De Gramont A, Gastiaburu J, Tournigand C, et al. Oxaliplatin with high-dose folinic acid and 5-fluorouracil 48 h infusion in pretreated metastatic colorectal cancer. Proc Am Soc Oncol 1994 ; 13 : 220.
36. Lévi F, Zidani R, Giachetti S, et al. Chronomodulation of combined platinum complexes and 5-fluorouracil delivery. Proc of 7th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Amsterdam, 1995 ; abst. 135.
37. Bertheault-Cvitkovic F, Jami A, Itzhaki M, et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and folinic acid in patients with metastatic colorectal cancer. J Clin Oncol 1996 ; 14 : 2950-8.
38. De Gramont A, Tournigand C, Louvet C, et al. High-dose folinic acid, 5-fluorouracil 48h-infusion and oxaliplatin in metastatic colorectal cancer. Proc of the Fifth International Congress on Anti-Cancer Chemotherapy, Paris 1995 ; abst. O269.
39. De Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose folinic acid and 5-fluorouracil 48 h infusion in pretreated metastatic colorectal cancer (CRC). Eur J Cancer 1995 ; 31A, suppl. 5, abst. 716.
40. Lévi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 1992 ; 69 (4) : 893-9.
41. Lévi F, Dogliotti L, Perpoint B, et al. Ambulatory intensified 4-day (d) every 2 weeks chronotherapy with oxaliplatin (L-OHP), 5-fluorouracil (5FU) and folinic acid (FA) in patients (pts) with metastatic colorectal cancer (MCC). Proc Am Soc Oncol 1995 ; 14 : 223.
42. Lévi F, Zidani R, Vannetzel JM, et al. Chronomodulated versus flat infusion of 5-fluorouracil (5FU), folinic acid (FA) and oxaliplatin (L-OHP) against metastatic colorectal cancer (MCC) in 2 consecutive european randomized multicenter trials (T). Proc Am Soc Oncol 1995 ; 14 : 204.
43. Giacchetti S, Gruia G, Itzhaki M, et al. Surgery after chronomodulated chemotherapy with 5-fluorouracil (5FU), folinic acid (FA) and oxaliplatin (L-OHP) (chrono) allows long term survival of patients (pts) with unresectable colorectal liver metastases. Proc Am Soc Oncol 1995 ; 14 : 204.
44. Garufi C, Bensmaïne MA, Brienza S, et al. Addition of oxaliplatin to chronomodulated 5FU and folinic acid for reversal of acquired chemoresistance in patients with advanced colorectal cancer. Proc ISPCC 1995 ; abst S125.
45. Extra M, De Gramont A, Gamelin E, et al. Oxaliplatin (L-OHP) synergistic clinical activity with 5-fluorouracil (5FU) in 5FU resistant colorectal cancer patients is independent of the 5FU administration modality and/or modulation by folinic acid. Proc NCI-EORTC 1996 ; 69 : abst. 236.
46. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996 ; 334 : 1-6.
47. Chollet P, Bensmaïne MA, Brienza S. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 1996 ; 7 : 1065-70.
48. Levin L, Simon R, Hryniuk W. Importance of multiagent chemotherapy regimens in ovarian carcinoma : dose intensity analysis. J Natl Cancer Inst 1993 ; 85 : 1732-42.
49. Kaye SB, Lewis CR, Paul J, et al. Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992 ; 340 : 329-33.
50. McGuire W, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a gynecologic oncology group study. J Clin Oncol 1995 ; 13 : 1589-99.
51. Cvitkovic E, Bensmaïne MA, Soulié P, et al. High activity of combined oxaliplatin (L-OHP)-cisplatin as salvage treatment in pretreated ovarian cancer. Proc of 7th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 1995 ; abst. S125.
52. Monnet I, Brienza S, Voisin S, et al. Phase II study of oxaliplatin (L-OHP) in patients with advanced non small cell lung cancer (NSCLC) : preliminary results. Eur J Cancer 1993 ; 29A, S763, abst. 901.
53. Gastiaburu J, Brienza S, Rotarski M, et al. Oxaliplatin (L-OHP): a new platinum analog, active in refractory/relapsed intermediate and low grade LNH. A phase II study. ECCO 7, Jerusalem, 1993 ; abst. 980.
54. Cavalli F, Jungi WF, Nissen NI, et al. Phase II trial, of cis-dichlorodiam-mineplatinum (II) in advanced malignant lymphoma : a study of the cancer and acute leukemia group B. Cancer 1981 ; 48 : 1927-30.
55. Degardin M, Cappelaere P, Krakowski I, et al. Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck. Oral Oncol, Eur J Cancer 1996 ; 32B (4) : 278-9.
56. Recondo G, Armand JP, Tellez-Bernal E, et al. Recurrent and/or metastatic head and neck squamous cell carcinoma : a clinical, univariate and multivariate analysis of response and syrvival with cisplatin-based chemotherapy. Laryngoscope 1991 ; 101 : 494-501.